Protalix BioTherapeutics Q1 Earnings Preview: Revenue & EPS Estimates Soar

Protalix BioTherapeutics is set to announce Q1 earnings on May 9th. The consensus EPS estimate is $0.08, a 233.3% YoY increase, and the consensus revenue estimate is $21.6M, a 476.0% YoY increase. Over the last year, PLX has seen significant growth in both EPS and revenue estimates.

Protalix BioTherapeutics, Inc. (PLX), a biopharmaceutical company focused on the development, production, and commercialization of recombinant therapeutic proteins, is set to announce its first quarter (Q1) 2025 earnings on May 9th, 2025. The consensus estimate for earnings per share (EPS) is $0.08, representing a 233.3% year-over-year (YoY) increase, while the consensus revenue estimate is $21.6 million, indicating a 476.0% YoY increase. These figures reflect significant growth in both EPS and revenue estimates over the past year.

The company's strong performance can be attributed to its innovative ProCellEx® plant cell-based protein expression system, which has enabled the development of several therapeutic protein candidates. These include Elelyso for Gaucher disease, PRX-102 for Fabry disease, PRX-110 for cystic fibrosis, PRX-115 for gout, and PRX-119 for NETs-related diseases. Additionally, strategic partnerships with pharmaceutical giants such as Pfizer and Chiesi Farmaceutici S.p.A. have contributed to Protalix's growth trajectory.

Management will host a conference call to discuss the financial results and provide an update on recent corporate and regulatory developments. The call is scheduled for 8:30 a.m. Eastern Daylight Time (EDT) on May 9th, 2025. Investors and analysts are eagerly awaiting these announcements to gain insights into the company's financial health and future prospects.

References:
[1] https://quantisnow.com/company/PLX